What is MARIZYME INC's earnings per share (EPS)?

MARIZYME INC (MRZM) reported diluted earnings per share of -$1.53 for fiscal year 2023. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

MARIZYME INC (MRZM) Financials

MRZM

FY2023 annual

Revenue $646K +176.6% YoY

Net Income -$69.5M -82.2% YoY

EPS (Diluted) -$1.53 YoY not available

Operating Cash Flow -$4.7M +56.8% YoY

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2024, ended Sep 30, 2024 Reported Mar 5, 2025 Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2024, filed Mar 5, 2025. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the MRZM SEC filings page.

MARIZYME INC (MRZM) reported $646K in revenue for fiscal year 2023, up 176.6% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI MRZM FY2023 2026-10-03

Marizyme’s revenue expanded, but escalating losses, shrinking liquidity, and negative equity show a business still financed externally.

Revenue increased to $646K in FY2023, yet gross margin fell from 76.7% in the prior year, so growth did not preserve unit economics. Operating margin improved to -52.8% even as net margin deteriorated to -107.7%, indicating below-operating items materially deepened the bottom-line loss.

By FY2023, liabilities exceeded assets—$28.7M versus $22.0M—leaving equity negative. A current ratio of 0.04x and reported liquidity of 0.4 months of annual operating outflow show that short-term obligations were not matched by readily available resources.

Operating cash outflow narrowed from $10.9M to $4.7M, even as net loss widened, so cash use and accounting loss moved in different directions. R&D reached $2.2M versus revenue of $646K, reinforcing that current operations remain development-led rather than commercially scaled.

Financial Health Signals

Financial health score not available

MARIZYME INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Distress

-16.15

MARIZYME INC scores -16.15, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($40K) relative to total liabilities ($28.7M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

2/8

MARIZYME INC passes 2 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.

Earnings Quality No Cash Backing

N/A

MARIZYME INC reported a net loss of $69.5M while operations used $4.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$1.2M

YoY+73.2%

QoQ+15.1%

MARIZYME INC's EBITDA was -$1.2M in Q3 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 73.2% from the same quarter a year earlier. Against the prior quarter it is up 15.1%.

Net Income

-$2.0M

YoY+92.6%

QoQ+73.6%

MARIZYME INC reported -$2.0M in net income in Q3 2024. This represents an increase of 92.6% from the same quarter a year earlier. Against the prior quarter it is up 73.6%.

EPS (Diluted)

-$0.01

MARIZYME INC earned -$0.01 per diluted share (EPS) in Q3 2024.

Revenue

Not reported for Q3 2024.

Cash & Balance Sheet

Cash & Debt

$64K

YoY-86.6%

QoQ+1120.5%

10Y CAGR-21.7%

MARIZYME INC held $64K in cash as of Q3 2024; long-term debt is not reported for that period.

Shares Outstanding

132M

5Y CAGR+46.0%

MARIZYME INC had 132M shares outstanding in Q3 2024.

Free Cash Flow

Not reported for Q3 2024.

Dividends Per Share

Not reported for Q3 2024.

Margins & Returns

None of these metrics is reported for Q3 2024.

Capital Allocation

R&D Spending

$344K

YoY-30.1%

QoQ+10.2%

MARIZYME INC invested $344K in research and development in Q3 2024. This represents a decrease of 30.1% from the same quarter a year earlier. Against the prior quarter it is up 10.2%.

Share Buybacks

Not reported for Q3 2024.

Capital Expenditures

Not reported for Q3 2024.

MRZM Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

MRZM quarterly income statement

Metric	TTM	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K	FY1010-K
Revenue	N/A	$646K+176.6%	$233K+11.0%	$210K+6.7%	$197K	$0-100.0%	$20K-80.0%	$101K-65.2%	$291K-28.6%	$408K	$0	$0-100.0%	$21.2M-25.0%	$28.3M+2.9%	$27.5M
Cost of Revenue	N/A	$188K+246.3%	$54K-32.4%	$80K	N/A	$0-100.0%	$20K-76.9%	$87K-58.3%	$208K-9.5%	$230K	$0	$0-100.0%	$14.6M-8.1%	$15.9M+13.9%	$14.0M
Gross Profit	N/A	$458K+155.5%	$179K+37.9%	$130K	N/A	$0-100.0%	$113-99.2%	$14K-82.8%	$83K-53.3%	$177K	$0	$0-100.0%	$45K-99.6%	$12.4M-8.4%	$13.5M
R&D Expenses	$1.4M	$2.2M-45.3%	$4.0M+136.6%	$1.7M+144.6%	$688K	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	N/A	N/A	N/A	N/A	$111K-12.5%	$127K+5379.7%	$2K	$0	$0-100.0%	$15K-91.1%	$167K+78.6%	$93K-98.5%	$6.2M+61.3%	$3.8M
Operating Income	-$26.6M	-$34.1M+8.7%	-$37.3M-323.1%	-$8.8M-52.1%	-$5.8M-448.1%	-$1.1M-328.1%	-$247K-97.8%	-$125K+31.3%	-$182K+84.7%	-$1.2M+2.9%	-$1.2M+43.9%	-$2.2M+23.1%	-$2.8M+71.9%	-$10.1M-411.9%	-$2.0M
EBITDA	N/A	-$33.2M+8.9%	-$36.5M-315.6%	-$8.8M-68.5%	-$5.2M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$1.3M+130.3%	-$4.3M-611.8%	$840K
Interest Expense	N/A	N/A	N/A	N/A	$45K	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$480K+18.1%	$406K-13.0%	$467K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$1.4M+166.6%	-$2.2M+33.9%	-$3.3M
Net Income	-$19.1M	-$69.5M-82.2%	-$38.2M-247.0%	-$11.0M-88.2%	-$5.8M-452.4%	-$1.1M-325.4%	-$249K+56.4%	-$571K+34.6%	-$873K+90.4%	-$9.0M+11.6%	-$10.2M-321.2%	-$2.4M+4.6%	-$2.5M+79.1%	-$12.2M-519.0%	-$2.0M
EPS (Basic)	N/A	-$1.53-62.8%	-$0.94-203.2%	-$0.31	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	-$0.13	-$1.53	-$0.94	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	45M	41M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'2410-Q	Q2'2410-Q	Q1'2410-Q	Q4'2310-Q	Q3'2310-Q	Q2'2310-Q	Q1'2310-Q	Q4'2210-K
Revenue	N/A	N/A	$33K-74.5%	$151K	$182K+138.8%	$185K+198.9%	$129K	N/A
Cost of Revenue	N/A	N/A	$10K-75.4%	$48K	$51K+228.9%	$50K+350.0%	$39K	N/A
Gross Profit	N/A	N/A	$23K-74.1%	$102K	$131K+115.7%	$135K+166.1%	$90K	N/A
R&D Expenses	$344K-30.1%	$312K-54.8%	$322K-46.9%	$387K	$492K-30.5%	$691K-49.6%	$606K-50.3%	N/A
Operating Income	-$1.4M+72.1%	-$1.6M+66.9%	-$1.4M+35.7%	-$22.3M	-$4.9M-117.5%	-$4.8M-4.4%	-$2.1M+46.6%	N/A
EBITDA	-$1.2M+73.2%	-$1.5M+68.0%	-$1.3M+34.3%	-$22.1M	-$4.6M-129.7%	-$4.6M-4.6%	-$1.9M+49.2%	N/A
Net Income	-$2.0M+92.6%	-$7.4M+79.4%	-$5.4M-111.2%	-$4.4M	-$26.5M-1609.8%	-$36.1M-421.1%	-$2.6M+58.3%	N/A
EPS (Basic)	-$0.01+98.3%	-$0.06+92.9%	-$0.04+33.3%	-$0.02+96.6%	-$0.58-1350.0%	-$0.84-394.1%	-$0.06+60.0%	-$0.58-262.5%
EPS (Diluted)	-$0.01	-$0.06	-$0.04	-$0.02	-$0.58-1350.0%	-$0.84-394.1%	-$0.06	-$0.58
Diluted Shares (Avg)	132M	132M	132M	N/A	46M+12.2%	43M+5.8%	41M	N/A

Not reported in any period shown, so not listed: SG&A Expenses, Interest Expense, Income Tax.

MRZM Balance Sheet

MRZM quarterly balance sheet

Metric	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K	FY1010-K
Total Assets	$22.0M-43.1%	$38.7M-41.4%	$66.0M+40.2%	$47.1M+64.5%	$28.6M0.0%	$28.6M+915.1%	$2.8M-7.4%	$3.0M-61.5%	$7.9M-46.8%	$14.9M-38.4%	$24.1M-19.3%	$29.9M-56.5%	$68.7M+13.6%	$60.5M
Current Assets	$969K-50.5%	$2.0M-55.6%	$4.4M+41.7%	$3.1M+3451096.7%	$90-99.6%	$20K-90.4%	$209K-42.0%	$361K-92.6%	$4.9M-7.3%	$5.3M-35.2%	$8.1M-45.9%	$15.0M+50.1%	$10.0M-9.1%	$11.0M
Cash & Equivalents	$148K-70.9%	$511K-87.5%	$4.1M+40.3%	$2.9M+3225191.1%	$90-13.5%	$104-99.8%	$52K+334.3%	$12K-17.3%	$14K+1544.1%	$874+1.6%	$860-99.9%	$719K-57.3%	$1.7M-9.9%	$1.9M
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$25K-88.5%	$216K+864.4%	$22K-60.3%	$56K	$0	N/A	N/A	N/A	N/A	N/A	N/A	$0-100.0%	$237K	$0
Accounts Receivable	$60K-31.3%	$88K+915.0%	$9K-78.7%	$41K	$0	N/A	$131K+717.3%	$16K-6.0%	$17K0.0%	$17K-95.4%	$367K+35.0%	$272K-94.4%	$4.9M-15.1%	$5.7M
Long-Term Investments	$0	$0	$0	$0	$0	$0-100.0%	$2.6M	$0	$0	$0	$0-100.0%	$428K-22.0%	$549K	$0
Goodwill	$5.4M-24.7%	$7.2M0.0%	$7.2M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$39.2M+126489.1%	$31K
Total Liabilities	$28.7M+35.0%	$21.3M+16.1%	$18.3M+919.5%	$1.8M+564.6%	$270K+531.6%	$43K-93.4%	$653K+124.2%	$291K-93.2%	$4.3M+95.4%	$2.2M+69.4%	$1.3M-75.6%	$5.3M-78.7%	$24.9M+11.4%	$22.4M
Current Liabilities	$22.6M+675.0%	$2.9M-6.8%	$3.1M+334.4%	$721K+167.0%	$270K+531.6%	$43K-93.4%	$653K+124.2%	$291K-93.2%	$4.3M+95.4%	$2.2M+69.4%	$1.3M-75.6%	$5.3M-72.2%	$19.1M+24.3%	$15.3M
Non-Current Liabilities	$6.1M-66.9%	$18.3M+20.9%	$15.2M+1312.3%	$1.1M	$0	$0	$0	$0	$0	$0	$0	$0-100.0%	$5.9M-16.7%	$7.1M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$3.7M+7.3%	$3.5M+343.6%	$781K
Total Equity	-$6.7M-138.5%	$17.4M-63.5%	$47.7M+5.3%	$45.3M+59.8%	$28.3M-0.8%	$28.6M+1218.9%	$2.2M-21.3%	$2.8M-24.1%	$3.6M-71.4%	$12.7M-44.5%	$22.8M-7.2%	$24.6M-31.3%	$35.8M-6.0%	$38.1M
Retained Earnings	-$155.5M-80.9%	-$86.0M-79.8%	-$47.8M-29.9%	-$36.8M-18.9%	-$31.0M-3.5%	-$29.9M-8.2%	-$27.7M-5.5%	-$26.2M-52.7%	-$17.2M-147.8%	-$6.9M-54.0%	-$4.5M-130.6%	-$1.9M+84.0%	-$12.1M-22587.3%	-$54K

Metric	Q3'2410-Q	Q2'2410-Q	Q1'2410-Q	Q4'2310-Q	Q3'2310-Q	Q2'2310-Q	Q1'2310-Q	Q4'2210-K
Total Assets	$21.3M-42.4%	$21.5M-41.8%	$21.6M-43.6%	$22.0M-43.1%	$36.9M-42.1%	$37.0M-42.5%	$38.3M-41.1%	$38.7M-41.4%
Current Assets	$855K-35.0%	$922K-12.9%	$735K-60.9%	$969K-50.5%	$1.3M-43.9%	$1.1M-59.5%	$1.9M-49.1%	$2.0M-55.6%
Cash & Equivalents	$64K-86.6%	$5K-97.5%	$6K-98.1%	$148K-70.9%	$475K-59.8%	$205K-90.0%	$330K-89.6%	$511K-87.5%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$27K-72.9%	$27K-80.8%	$15K-91.4%	$25K-88.5%	$99K-60.6%	$140K-47.9%	$177K+1036.3%	$216K+864.4%
Accounts Receivable	$2K-95.4%	N/A	N/A	$60K-31.3%	$43K-20.3%	$73K+37.5%	$78K+803.7%	$88K+915.0%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$5.4M-24.7%	$5.4M-24.7%	$5.4M-24.7%	$5.4M-24.7%	$7.2M0.0%	$7.2M0.0%	$7.2M0.0%	$7.2M0.0%
Total Liabilities	$36.8M-44.5%	$35.5M-17.6%	$32.2M+39.8%	$28.7M+35.0%	$66.3M+191.2%	$43.1M+87.6%	$23.0M+16.6%	$21.3M+16.1%
Current Liabilities	$30.0M-46.6%	$28.1M-17.7%	$25.7M+219.5%	$22.6M+675.0%	$56.1M+3394.3%	$34.2M+2177.8%	$8.0M+384.7%	$2.9M-6.8%
Non-Current Liabilities	$6.8M-33.2%	$7.4M-17.2%	$6.6M-56.3%	$6.1M-66.9%	$10.2M-51.8%	$8.9M-58.6%	$15.0M-17.1%	$18.3M+20.9%
Total Equity	-$15.5M+47.1%	-$14.0M-129.3%	-$10.6M-169.8%	-$6.7M-138.5%	-$29.4M-171.8%	-$6.1M-114.7%	$15.2M-66.3%	$17.4M-63.5%
Retained Earnings	-$170.3M-12.7%	-$168.4M-35.1%	-$160.9M-81.7%	-$155.5M-80.9%	-$151.2M-142.2%	-$124.6M-104.7%	-$88.5M-64.1%	-$86.0M-79.8%

Not reported in any period shown, so not listed: Long-Term Debt.

MRZM Cash Flow Statement

MRZM quarterly cash flow statement

Metric	TTM	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K	FY1010-K
Operating Cash Flow	-$3.7M	-$4.7M+56.8%	-$10.9M-87.5%	-$5.8M-79.5%	-$3.2M-2778.1%	-$112K+48.8%	-$219K+67.6%	-$676K-521.0%	$161K+202.5%	-$157K+78.9%	-$742K-136.4%	$2.0M+158.4%	-$3.5M+80.3%	-$17.7M-250.6%	$11.7M
Depreciation & Amortization	N/A	$841K0.0%	$841K+1818.0%	$44K-92.6%	$591K	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$4.1M-29.0%	$5.8M+107.1%	$2.8M
Stock-Based Compensation	N/A	$527K-72.4%	$1.9M+120.3%	$865K-34.9%	$1.3M+90.3%	$699K	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Capital Expenditures	N/A	N/A	N/A	N/A	$149K+1043.5%	$13K+838.0%	$1K	$0	$0	$0	$0	$0-100.0%	-$139K	$0-100.0%	$161K
Free Cash Flow	N/A	N/A	N/A	N/A	-$3.4M-2597.7%	-$125K+43.3%	-$220K+67.4%	-$676K-521.0%	$161K+202.5%	-$157K+78.9%	-$742K-136.4%	$2.0M+156.1%	-$3.6M+79.5%	-$17.7M-252.7%	$11.6M
Investing Cash Flow	N/A	N/A	N/A	N/A	-$149K-1043.5%	-$13K-838.0%	-$1K	$0+100.0%	-$1.2M-793.2%	-$132K-148.6%	$272K+203.1%	-$264K+60.8%	-$673K-109.1%	$7.4M+198.6%	-$7.5M
Financing Cash Flow	$3.3M	$4.3M-40.7%	$7.3M+4.8%	$7.0M+10.9%	$6.3M+4920.1%	$125K-25.9%	$169K-76.4%	$715K+538.9%	-$163K-153.9%	$302K-35.6%	$469K+118.8%	-$2.5M-177.9%	$3.2M-74.8%	$12.7M+1344.2%	-$1.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	$2.0M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'2410-Q	Q2'2410-Q	Q1'2410-Q	Q4'2310-Q	Q3'2310-Q	Q2'2310-Q	Q1'2310-Q	Q4'2210-K
Operating Cash Flow	-$983K+14.7%	-$733K+38.8%	-$809K+27.8%	-$1.2M+23.5%	-$1.2M+47.8%	-$1.2M+56.3%	-$1.1M+74.0%	-$1.6M-7.6%
Depreciation & Amortization	$109K-48.3%	$121K-42.3%	$109K-48.3%	$210K0.0%	$210K0.0%	$210K0.0%	$210K0.0%	$210K
Stock-Based Compensation	$21K-75.9%	$42K-74.1%	$54K-74.3%	N/A	$86K-68.3%	$161K-76.2%	$211K-70.6%	N/A
Financing Cash Flow	$1.0M-26.8%	$732K-31.8%	$667K-29.0%	$887K-3.0%	$1.4M+5.6%	$1.1M-33.5%	$939K-72.5%	$915K-83.5%

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.

MRZM Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

MRZM quarterly financial ratios

Metric	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K	FY1010-K
Gross Margin	70.9%-5.9pp	76.7%+14.9pp	61.8%	N/A	N/A	0.6%-13.5pp	14.1%-14.3pp	28.4%-15.1pp	43.5%	N/A	N/A	0.2%-43.6pp	43.8%-5.4pp	49.2%
Operating Margin	-5278.1%	-15985.5%	-4195.1%	-2941.9%	N/A	-1224.2%	-123.5%	-62.5%	-292.1%	N/A	N/A	-13.4%+22.4pp	-35.9%-28.6pp	-7.2%
Net Margin	-10767.8%	-16346.2%	-5230.2%	-2965.0%	N/A	-1232.2%	-563.9%	-299.8%	-2219.2%	N/A	N/A	-12.0%+31.0pp	-43.0%-35.9pp	-7.1%
Return on Equity	N/A	-219.1%-196.0pp	-23.1%-10.2pp	-12.9%-9.2pp	-3.7%-2.9pp	-0.9%+25.5pp	-26.3%+5.4pp	-31.7%+217.8pp	-249.5%-168.8pp	-80.8%-70.1pp	-10.7%-0.3pp	-10.4%+23.6pp	-34.0%-28.8pp	-5.2%
Return on Assets	-315.9%-217.2pp	-98.7%-82.0pp	-16.7%-4.3pp	-12.4%-8.7pp	-3.7%-2.8pp	-0.9%+19.4pp	-20.2%+8.4pp	-28.7%+85.7pp	-114.3%-45.5pp	-68.8%-58.8pp	-10.1%-1.6pp	-8.5%+9.2pp	-17.7%-14.5pp	-3.3%
Current Ratio	0.04-0.6x	0.67-0.7x	1.40-2.9x	4.31+4.3x	0.00-0.5x	0.47+0.1x	0.32-0.9x	1.24+0.1x	1.14-1.3x	2.40-3.9x	6.26+3.4x	2.83+2.3x	0.52-0.2x	0.72
Debt-to-Equity	N/A	1.22+0.8x	0.38+0.3x	0.040.0x	0.010.0x	0.00-0.3x	0.30+0.2x	0.11-1.1x	1.18+1.0x	0.17+0.1x	0.06-0.1x	0.15+0.1x	0.10+0.1x	0.02
Asset Turnover	0.030.0x	0.010.0x	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.04-0.1x	0.100.0x	0.05+0.1x	0.000.0x	0.00-0.7x	0.71+0.3x	0.410.0x	0.45
FCF Margin	N/A	N/A	N/A	-1710.7%	N/A	-1091.2%	-667.8%	55.1%+93.5pp	-38.4%	N/A	N/A	-17.2%+45.5pp	-62.6%-104.8pp	42.2%

Metric	Q3'2410-Q	Q2'2410-Q	Q1'2410-Q	Q4'2310-Q	Q3'2310-Q	Q2'2310-Q	Q1'2310-Q	Q4'2210-K
Gross Margin	N/A	N/A	70.6%+1.1pp	68.0%	71.9%-7.7pp	73.2%-9.0pp	69.5%	N/A
Operating Margin	N/A	N/A	-4176.2%	-14806.1%	-2675.6%	-2600.4%	-1653.7%	N/A
Net Margin	N/A	N/A	-16425.2%	-2891.9%	-14623.4%	-19532.4%	-1980.7%	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	-16.8%-3.2pp	N/A
Return on Assets	-9.2%+62.7pp	-34.5%+63.0pp	-25.0%-18.3pp	-19.8%	-71.9%-69.5pp	-97.6%-86.8pp	-6.7%+2.7pp	N/A
Current Ratio	0.030.0x	0.030.0x	0.03-0.2x	0.04-0.6x	0.02-1.4x	0.03-1.7x	0.23-2.0x	0.67-0.7x
Debt-to-Equity	N/A	N/A	N/A	N/A	N/A	N/A	1.51+1.1x	1.22+0.8x
Asset Turnover	N/A	N/A	0.000.0x	0.01	0.000.0x	0.010.0x	0.00	N/A

Not reported in any period shown, so not listed: FCF Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.

Note: Shareholder equity is negative (-$6.7M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.04), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
MARIZYME INC MRZM	FY2023	$646K	-$69.5M	N/A	$40K	—
SYROS PHARMACEUTICALS INC SYRS	FY2023	$9.9M	-$164.6M	N/A	$3.1M	—
ARIDIS PHARMACEUTICAL INC ARDS	FY2022	$3.1M	-$30.4M	N/A	$4K	—
PAXMEDICA INC PXMD	FY2023	$0	-$18.3M	N/A	$2.8M	—

Where MARIZYME INC Ranks

Frequently Asked Questions

What is MARIZYME INC's annual revenue?

MARIZYME INC (MRZM) reported $646K in total revenue for fiscal year 2023. This represents a 176.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is MARIZYME INC's revenue growing?

MARIZYME INC (MRZM) revenue grew by 176.6% year-over-year, from $233K to $646K in fiscal year 2023.

Is MARIZYME INC profitable?

No, MARIZYME INC (MRZM) reported a net income of -$69.5M in fiscal year 2023.

What is MARIZYME INC's EBITDA?

MARIZYME INC (MRZM) had EBITDA of -$33.2M in fiscal year 2023, measuring earnings before interest, taxes, depreciation, and amortization.

What is MARIZYME INC's gross margin?

MARIZYME INC (MRZM) had a gross margin of 70.9% in fiscal year 2023, indicating the percentage of revenue retained after direct costs of goods sold.

What is MARIZYME INC's operating cash flow?

MARIZYME INC (MRZM) recorded an outflow of $4.7M in operating cash flow during fiscal year 2023, representing cash used by core business activities.

What are MARIZYME INC's total assets?

MARIZYME INC (MRZM) had $22.0M in total assets as of fiscal year 2023, including both current and long-term assets.

How much does MARIZYME INC spend on research and development?

MARIZYME INC (MRZM) invested $2.2M in research and development during fiscal year 2023.

How many shares does MARIZYME INC have outstanding?

MARIZYME INC (MRZM) had 132M shares outstanding as of fiscal year 2023.

What is MARIZYME INC's current ratio?

MARIZYME INC (MRZM) had a current ratio of 0.04 as of fiscal year 2023, which is below 1.0, which may suggest potential liquidity concerns.

What is MARIZYME INC's return on assets (ROA)?

MARIZYME INC (MRZM) had a return on assets of -315.9% for fiscal year 2023, measuring how efficiently the company uses its assets to generate profit.

How does MARIZYME INC's liquidity compare with its operating cash outflow?

At the end of fiscal year 2023, MARIZYME INC (MRZM) held $148K in cash, cash equivalents and investments, and reported an operating cash outflow of $4.7M over that year. Dividing the one by the other, the reported balance equals about 0 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Why is MARIZYME INC's debt-to-equity ratio negative or not reported?

MARIZYME INC (MRZM) has negative shareholder equity of -$6.7M as of fiscal year 2023, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is MARIZYME INC's Altman Z-Score?

MARIZYME INC (MRZM) has an Altman Z-Score of -16.15, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is MARIZYME INC's Piotroski F-Score?

MARIZYME INC (MRZM) has a Piotroski F-Score of 2 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are MARIZYME INC's earnings high quality?

MARIZYME INC (MRZM) reported a net loss of $69.5M while operations used $4.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.